Presented by: prof. dr. Wiro Niessen & dr. Harro Seelaar
This ACE lecture traces the path of an artificial intelligence radiology application that was originally developed within Erasmus MC as academic tool, but has now found its way to daily clinical practice, enabling individual patient decision-making in dementia and related brain abnormalities.
Presented by: Dr. B. Groot Koerkamp
Bas Groot Koerkamp is a surgical oncologist and transplant surgeon in the ACE Hepato-Pancreato-Biliary Diseases. In this ACE lecture on regional chemotherapy for liver tumors, he explains the challenges of introducing an old treatment for colorectal liver metastases and intrahepatic cholangiocarcinoma.
Presented by: dr. Wendy van de Sande
In this lecture we will learn about the neglected tropical disease mycetoma for which currently the only option is to remove the infected lesions surgically or to amputate the infected limb. Characteristic of this disease is that the micro-organisms causing this infection build a protective structure called a grain inside the infected tissue. We will take the audience along our journey to find clues how this structure is formed. How we try to use this information to design drugs which are effective against mycetoma and how we have involved an open source drug discovery project in order to solve these issues.
Presented by: Prof. dr. John Martens
Sustainable health care heavily relies on powerful biomarkers. The ACE InnovaBIM (Innovative Biomarkers In Medicine) aims to develop tissue- and bodyfluid-derived biomarkers. Implementation of beyond state-of-the-art biomarkers developed within our ACE.
Dr. Birgit Koch, Dr. Sinno Simons and Laura Peeters, PhD Candidate
In this lecture womb to grave pharmacology is discussed. Amongst all pharmacokinetics, pharmacodynamics, therapeutic drug monitoring and toxicology in research, education and clinical setting are introduced in this lecture. Current pharmacotherapy is most often based on one dose fits all strategy. In our ACE our focus is to individualize pharmacotherapy and to optimize dosing, moving towards a ‘one dose fits one’ strategy.